ABSTRACT

Most of Solute carrier family-2 (SLC2) members play a key role of facilitative transporters, and glucose transporter (GLUT) proteins encoded by SLC2s can transport hexoses or polyols. However, the function and mechanism of SLC2s remain unclear in human cancers. Here, we explored the dysregulated expression, prognostic values, epigenetic, genetic alterations, and biomolecular network of SLC2s in human cancers. According to the data from public-omicsrepository, SLC2A4 (GLUT4) was found to be significantly downregulated in most cancers, and higher messenger RNA (mRNA) expression of SLC2A4 significantly associated with better prognosis of breast cancer (BRCA) patients. Moreover, DNA hypermethylation in the promoter of SLC2A4 may affect the regulation of its mRNA expression, and SLC2A4 was strongly correlated with pathways, including the translocation of SLC2A4 to the plasma membrane and PID INSULIN PATHWAY. In conclusion, these results provide insight into SLC2s in human cancers and suggest that SLC2A4 could be an unfavorable prognostic biomarker for the survival of BRCA patients.

摘要

大多数溶质载体家族 2 (SLC2) 成员在促进转运蛋白中发挥关键作用，由SLC2s编码的葡萄糖转运蛋白 (GLUT) 蛋白可以转运己糖或多元醇。然而，SLC2s在人类癌症中的功能和机制仍不清楚。在这里，我们探讨了SLC2在人类癌症中的失调表达、预后价值、表观遗传、遗传改变和生物分子网络。根据来自公共组学存储库的数据，发现SLC2A4 ( GLUT4 ) 在大多数癌症中显着下调，并且SLC2A4的信使 RNA (mRNA) 表达更高与乳腺癌（BRCA）患者更好的预后显着相关。此外，SLC2A4启动子中的 DNA 高甲基化可能影响其 mRNA 表达的调节，并且SLC2A4与SLC2A4易位至质膜和 PID INSULIN PATHWAY 等途径密切相关。总之，这些结果提供了对人类癌症中 SLC2 的深入了解，并表明SLC2A4可能是 BRCA 患者生存的不利预后生物标志物。